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The metals cadmium and lead are ubiquitous
environmental pollutants of increasing world-
wide concern because of their renal toxicity and
long residence time in the kidney [International
Programme on Chemical Safety (IPCS) 1992;
Jarup et al. 1998; Madden and Fowler 2000;
Satarug et al. 2000]. These metals are absorbed
by the body via enteral and pulmonary routes
from dietary sources, drinking water, and
polluted air (Bhatnagar 2004; IPCS 1992;
Galal-Gorchev 1993; Satarug et al. 2004b).
Safe levels of dietary intake, known as the pro-
visional tolerable weekly intake (PTWI), have
been established for Cd and Pb (World Health
Organization 1989). The PTWI for Pb is
25 µg/kg body weight/week, which is approxi-
mately three times more tolerated than Cd,
with a PTWI of 7 µg/kg body weight/week. Cd
accumulates in the liver and kidneys, whereas
Pb preferentially accumulates in the bone
(IPCS 1992; Satarug et al. 2002). Cd in liver
and Pb in bone are mobilizable to the kidney,
providing an opportunity for nephrotoxicity
with no additional exposure. The manifesta-
tions of Cd nephrotoxicity include proteinuria,
calciuria, aminoaciduria, glycosuria, and tubu-
lar necrosis (IPCS 1992; Jarup et al. 1998).
Chronic exposure to low-level Cd results
in 20- to 40-fold higher Cd concentration in
kidneys than in the liver. However, although
liver Cd levels are much lower than kidney
levels, suggestive evidence for liver effects of
Cd comes from immunoblotting of post-
mortem liver samples with anti-peptide anti-
body preparations against various human
drug-metabolizing enzymes of the cyto-
chrome P450 (CYP) superfamily, which
revealed correlation between tissue Cd con-
tents and the abundance of certain CYPs
(Baker et al. 2001, 2002, 2003). Pb effects on
liver drug metabolism were reported in early
studies, where diminished phenazone elimi-
nation rates in men who had been occupa-
tionally exposed to Pb and who had evidence
of clinical Pb poisoning were reversed after
the patients had been treated with EDTA
chelation therapy (Fischbein et al. 1977;
Meredith et al. 1977; Moore 2004). A pri-
mary effect of Pb that could cause depressed
CYP-mediated phenazone metabolism was its
reduction of heme bioavailability via Pb
induction of hepatic expression of the enzyme
heme oxygenase (Moore et al. 1987), which
degrades heme (Tenhunen et al. 1968) and
Pb inhibition of the enzyme δ-aminolevuli-
nate (ALA) synthase of heme synthesis path-
way (Moore et al. 1987). However, although
Cd is a potent inducer of heme oxygenase
(Alam et al. 1989, 2000; Rosenberg and
Kappas 1991) and an inhibitor of ALA syn-
thase (Fujita 1997), as is Pb, Cd also has the
ability to induce hepatic and renal cytochrome
P450 2A5 (CYP2A5) in mice (Abu-Bakar et al.
2004; Bartosiewicz et al. 2001; Urbenjapol
et al. 2001). The ability of Cd to induce the
murine CYP2A5, which is an ortholog of
human cytochrome P450 2A6 (CYP2A6), is
consistent with results obtained from a study in
healthy human subjects, which found a positive
correlation between Cd burden and accelerated
rate of hepatic coumarin metabolism known to
be mediated exclusively by CYP2A6 (Satarug
et al. 2004a).
CYP2A6 is one of the genetically poly-
morphic enzymes, known to be expressed
predominantly in the liver and to be an exclu-
sive catalyst of a conversion of coumarin to
7-hydroxycoumarin (7-OHC; Oscarson 2001;
Pelkonen et al. 2000; Raunio et al. 2001).
CYP2A6 metabolizes also the tobacco alkaloid
nicotine to cotinine, which is metabolized
further by CYP2A6 to 3´-hydroxycotinine
(Benowitz et al. 2003; Messina et al. 1997;
Nakajima et al. 1996). CYP2A6 is therefore
known also as nicotine C-oxidase, and its
phenotype, reflected by urinary 3´-hydroxy-
cotinine:cotinine ratio, showed a positive cor-
relation with daily cigarette consumption
Address correspondence to S. Satarug, National
Research Centre for Environmental Toxicology,
University of Queensland, 39 Kessels Rd., Coopers
Plains, Brisbane, Queensland 4108, Australia.
Telephone: 61-7-3000-9195. Fax: 61-7-3274-9003.
E-mail: s.satarug@uq.edu.au
We thank all volunteers for their enthusiastic
cooperation. We are grateful to C. Itthipanichpong
of the Pharmacology Department, Chulalongkorn
University, and B. Thititummatada of Ban Bangapi
School, Klong-gume, Bangkok, for their advice and
support.
The National Research Centre for Environmental
Toxicology is funded by Queensland Health, the
University of Queensland, Queensland University of
Technology, and Grifﬁth University.
The authors declare they have no competing
ﬁnancial interests.
Received 18 April 2004; accepted 28 July 2004.
Evidence for Concurrent Effects of Exposure to Environmental Cadmium 
and Lead on Hepatic CYP2A6 Phenotype and Renal Function Biomarkers 
in Nonsmokers
Soisungwan Satarug,1 Muneko Nishijo,2 Pailin Ujjin,3 Yuvaree Vanavanitkun,3 Jason R. Baker,4
and Michael R. Moore1,5
1National Research Centre for Environmental Toxicology, University of Queensland, Brisbane, Australia; 2Department of Public Health,
Kanazawa Medical University, Uchinada, Ishikawa, Japan; 3Department of Laboratory Medicine, Chulalongkorn University, Bangkok,
Thailand; 4Department of Clinical Pharmacology, Flinders University, Adelaide, Australia; 5Queensland Health Scientiﬁc Services,
Brisbane, Australia
We examined the interrelationships between phenotype of hepatic cytochrome P450 2A6
(CYP2A6), nephropathy, and exposure to cadmium and lead in a group of 118 healthy Thai men
and women who had never smoked. Their urinary Cd excretion ranged from 0.05 to 2.36 µg/g
creatinine, whereas their urinary Pb excretion ranged from 0.1 to 12 µg/g creatinine. Average age
and Cd burden of women and men did not differ. Women, however, on average showed a 46%
higher urinary Pb excretion (p < 0.001) and lower zinc status, suggested by lower average serum
Zn and urinary Zn excretion compared with those in men. Cd-linked nephropathy was detected in
both men and women. However, Pb-linked nephropathy was seen only in women, possibly
because of higher Pb burden coupled with lower protective factors, notably of Zn (p < 0.001), in
women compared with men. In men, Pb burden showed a negative association with CYP2A6
activity (adjusted β = –0.29, p = 0.003), whereas Cd burden showed a positive association with
CYP2A6 activity (adjusted β = 0.38, p = 0.001), suggesting opposing effects of Cd and Pb on
hepatic CYP2A6 phenotype. The weaker correlation between Cd burden CYP2A6 activity in
women despite similarity in Cd burden between men and women is consistent with opposing
effects of Pb and Cd on hepatic CYP2A6 phenotypic expression. A positive correlation between
Cd-linked nephropathy (urinary N-acetyl-β-D-glucosaminidase excretion) and CYP2A6 activity
in men (r = 0.39, p = 0.002) and women (r = 0.37, p = 0.001) suggests that Cd induction of
hepatic CYP2A6 expression and Cd-linked nephropathy occurred simultaneously. Key words:
β2-microglobulin, cadmium, coumarin, cytochrome P450 2A6, drug-metabolizing enzyme,
environmental exposure, lead, liver drug metabolism, N-acetyl-β-D-glucosaminidase, nicotine,
nicotine C-oxidase, proteinuria, zinc. Environ Health Perspect 112:1512–1518 (2004).
doi:10.1289/ehp.7192 available via http://dx.doi.org/ [Online 28 July 2004](Benowitz et al. 2003). Other substrates of
CYP2A6 include a number of pharmaceuticals
(methoxyﬂurane, halothane, losigamone, val-
proic acid, letrozole, fadrozole, disulﬁram, and
tegafur), the caffeine metabolite 17-dimethyl-
xanthine, the tobacco-specific nitrosamines,
and the tobacco alkaloid nicotine. Individuals
with the CYP2A6 gene deﬁciency were found
to be protected from smoking dependence.
This has led to the hypothesis that the CYP2A6
genetic polymorphism is a sole determinant of
individuals’ smoking dependence. Although
conﬂicting results have been reported, casting
doubt on such role of the CYP2A6 genetic
polymorphism (Tricker 2003). We hypothe-
size that CYP2A6 phenotypic variability seen
among most healthy individuals is caused by
their exposure to environmental substances,
which have the ability to induce or suppress
the hepatic CYP2A6 gene expression.
Evidence for inducibility of hepatic
CYP2A6 comes from studies showing that the
metals cobalt and tin, and drugs and com-
pounds of diverse structures such as pheno-
barbital, rifampicin, clofibrate, pyrazole,
thioacetamide, and griseofulvin increase
expression of murine CYP2A5, which is an
ortholog of human CYP2A6 (Donato et al.
2000; Oscarson 2001; Pelkonen et al. 2000;
Raunio et al. 2001). Some of these chemicals
were indeed found to induce also CYP2A6
expression in primary culture human hepato-
cytes (Donato et al. 2000). Previously, we
found that hepatic CYP2A6 activity was ele-
vated in individuals who had high Cd burden
(Satarug et al. 2004a), assessed by urinary Cd
excretion, which is a widely used indicator of
long-term Cd exposure (Lauwerys et al. 1994;
Mueller et al. 1998). However, in the previ-
ous study both smokers and nonsmokers were
included, which reflected mixed sources
of exposure and heterogeneity in exposure
pattern that may also have altered CYP2A6
phenotypic expression. Further, neither Pb
exposure, zinc status, nor markers of renal
tubular toxicity were determined for the pre-
vious subjects. The present study therefore
was conducted on another group of subjects
who had never smoked, to examine the asso-
ciation between increased hepatic CYP2A6
activity and dietary exposure to Cd. Another
purpose was to explore the potential effects of
Pb exposure, sex, age, and Zn and iron status,
assessed by serum Zn and ferritin levels, on
liver CYP2A6 phenotypic variability and
renal toxicity.
Materials and Methods
Studied subjects. This study was approved by
the Institutional Ethical Committee on Human
Experimentation, Chulalongkorn University
Hospital, Faculty of Medicine, Bangkok,
Thailand. The studies sample group consisted
of 118 individuals (65 women, 53 men),
21–57 years of age. All subjects were non-
smokers, and all were Thai nationals who took
part in the study after giving informed con-
sent. All subjects lived in residential areas sur-
rounding Bangkok when the study was
undertaken. Subjects were students, factory
workers, teachers, and laborers. Frequency dis-
tribution of various occupations in men and
women was similar. None of them had been
exposed to Cd in the workplace, and the group
was considered to represent the middle-class
Thai population in socioeconomic status.
Biologic sample collection. One 15-mL
blood sample was collected by venipuncture
from each subject 1 hr after swallowing of
one 15-mg coumarin tablet (Venalot, Schaper
and Brummer GmbH and Co. KG, Salgitter,
Germany) with 300 mL drinking water after
overnight fasting. Aliquots of the blood sam-
ples collected were subject to routine hema-
tology and clinical biochemistry analysis using
the blood analysis automated system of the
Chulalongkorn University Hospital. Serum
ferritin levels were assayed by an immuno-
electrochemiluminescence method (Boehringer
Mannheim Elecsys 1010; Boehringer Mann-
heim and Roche Diagnostics, Bangkok,
Thailand). Urine samples were also collected
for 3 hr after Venalot administration. The
urine samples from each subject were pooled
and total urinary volume was recorded. One
5-mL aliquot of urine from each subject was
analyzed for creatinine and routine urinalysis
(pH, speciﬁc gravity, protein, glucose) within
the day of collection. The remainder of the
urine samples, together with aliquots of whole
blood and serum samples, were stored at
–80°C for later analysis.
Analysis of biomarkers and metals. Urine
samples were analyzed for 7-OHC, Cd, total
protein, β2-microglobulin (β2-MG), and
N-acetyl-β-D-glucosaminidase (NAG). For
7-OHC analysis, urine samples were
treated with β-glucuronidase (250 U/mL;
Sigma-Aldrich, Sydney, Australia) in
1.0 M acetate buffer (pH 5.0) at 37°C for
30 min. Concentrations of 7-OHC in the
β-glucuronidase–treated samples were
quantified by the high-performance liquid
chromatography system with C18-reverse
phase column and a fluorescence detector
(Walters et al. 1980). Equivalent procedures
were conducted for determination of 7-OHC
concentration in serum samples.
Cd levels in urine samples were determined
by inductively coupled plasma mass spectrom-
etry. The accuracy and precision of our urine
metal analysis were assessed by a simultaneous
analysis of samples of the urine metal control
Lyphochek (Bio-Rad, Sydney, Australia). The
level 1 and level 2 urine metal controls refer to
the controls with different concentrations of
metals. The mean values for Cd and Zn in the
level 1 control urine were 6.2 and 713 µg/L,
respectively, and the mean values for the same
metals in the level 2 control urine were 11.2
and 1,176 µg/L. Our analysis of the level 1
control urine samples (n = 18) gave mean ± SD
values of 6.1 ± 0.2 and 662 ± 38 µg/L for Cd
and Zn, respectively. The coefﬁcient of varia-
tion for the corresponding metal was 2.5 and
5.6%. Our analysis of the level 2 control urine
samples (n = 18) gave mean ± SD values of
11.4 ± 0.3 and 1,077 ± 65 µg/L for Cd and
Zn. The coefficient of variation for the cor-
responding metal was 2.5 and 6.0%. A urinary
Cd concentration of 0.05 µg/L was assigned to
the urine sample found to contain Cd below
the detection limit of the method.
Protein in urine samples was determined
by turbidimetry after protein precipitation
with EDTA and benzethonium chloride
using the automated system (Roche/Hitachi
717; Boehringer Mannheim and Roche
Diagnostics). Urinary β2-MG was determined
by latex immunoagglutination method (LX
test, Eiken β2MG-II; Eiken and Shionogi
Co., Tokyo, Japan), and urinary NAG was
assessed with an enzymatic rate colorimetric
assay. Urine β2-MG and NAG assays were
conducted with automated systems. Urinary
Cd, protein, β2-MG, and NAG were adjusted
for creatinine excretion, and both creatinine-
adjusted values and total amount of each
analyte excreted in 3 hr were used. Similar
conclusions were reached with both values.
However, in evaluations for effects of Cd
exposure by correlation and regression analy-
ses, total amounts of Cd and renal function
biomarkers excreted in urine in 3 hr were used
because they related more significantly did
than creatinine-adjusted ﬁgures.
Statistical analysis. The Kolmogorov-
Smirnov goodness of ﬁt test was used to test
for conformity to normal distribution of
measured and base-10 logarithmically trans-
formed data (see details in “Results”). To
identify relationships between variables, the
statistical tests used were chi-square testing of
cross-tabulated data, Pearson’s correlation test
or Spearman’s rank correlation, and multiple
regression. We used the Student t-test or
Mann-Whitney rank-sum test to determine
statistical significance levels for male–female
differences in mean values of tested variables.
In multiple regression analyses, an indicator
of liver effect (CYP2A6 catalytic activity) was
entered as a criterion variable, whereas age
and urinary Cd, Pb, and Zn excretion were
entered as explanatory variables.
Results
Table 1 shows age and blood and urine chem-
istry profiles of men and women separately.
Average age was similar for men (37 years) and
women (38 years). Most measured parameters
were higher in men than in women: hemoglo-
bin, hematocrit, red blood cell counts, blood
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plasma creatinine concentrations (p-values,
< 0.001–0.005). Urinary Zn excretion in men
was 27% higher than in women (p = 0.001),
but men’s and women’s urinary Cd excretion
rates were similar. This produces a greater
mean urinary Zn:Cd ratio in men than in
women (p = 0.001). Average values for serum
Cd and Pb were similar in men and women.
However, average urinary Pb and urinary total
protein excretion rates were higher in women
than in men (p < 0.001 for urinary Pb and
p = 0.001–0.005 for urinary protein excre-
tion). On average, urinary β2-MG, NAG
excretion, and urinary 7-OHC excretion rates
were similar in men and women.
The distribution of the logarithmically
transformed Cd excretion rates conforms to
normal (Kolmogorov-Smirnov goodness of ﬁt
test, p = 0.99). The geometric mean, median,
and SD values were 54, 55, and 2.3 ng/3 hr,
respectively. The lowest and highest urinary
Cd excretion rates were 5 and 360 ng/3 hr,
respectively. The overall frequency distribu-
tion of men and women in Cd-burden groups
did not differ (likelihood ratio chi-squared =
2.6, p = 0.46; Figure 1A). The distribution of
urinary Pb excretion rates conformed to nor-
mal, with mean, median, and SD values of
0.25, 0.23, and 0.18 µg/3 hr, respectively
(Kolmogorov-Smirnov goodness of fit test,
p = 0.17). The lowest and highest urinary Pb
excretion rates were 0.01 and 1.06 µg/3 hr,
respectively. The frequency distribution of
men and women in Pb-burden groups dif-
fered significantly (likelihood ratio chi-
squared = 18, p < 0.001; Figure 1B).
The distribution of urinary 7-OHC excre-
tion rates was slightly skewed to the left of
normal, with mean, median, and SD values of
5.06, 4.73, and 3.15 mg/3 hr, respectively
(Kolmogorov-Smirnov goodness of fit test,
p = 0.57). The highest urinary 7-OHC excre-
tion rate was 15 mg/3 hr. Two men and one
woman did not excrete 7-OHC, most likely
because they lacked the CYP2A6 gene or have
a defect in the CYP2A6 gene expression. The
overall frequency distribution of men and
women in CYP2A6 phenotype groups showed
a tendency to be different (likelihood ratio
chi-squared = 7.3, p = 0.06; Figure 1C). Of
the seven subjects with a very rapid metabo-
lizer phenotype of CYP2A6, six were women.
Table 2 summarizes the relationship
between urinary Cd excretion, age, iron store
status, and biomarkers of kidney function. We
found no correlation between iron store status
and Cd burden in men or women, but a strong
positive correlation between urinary Cd excre-
tion and age was seen in men (r = 0.47,
p < 0.001). The correlation between urinary
Cd and age was weaker in women, and it was
not statistically signiﬁcant (r = 0.20, p = 0.06).
Both men’s and women’s urinary Cd excretion
correlated positively with urinary protein excre-
tion (overall r = 0.25, p = 0.003), but no cor-
relation was seen between urinary Cd and
β2-MG excretion in men or women. The cor-
relation between urinary protein and Cd excre-
tion in men and women remained statistically
significant after controlling for age (partial
r = 0.20, p = 0.02). Urinary NAG excretion
rates showed a strong positive correlation with
urinary Cd in both men and women (overall
r = 0.49, p < 0.001). Controlling for age did
not affect the strength of the NAG versus Cd
correlation (partial r = 0.48, p < 0.001).
Table 3 shows results of equivalent correla-
tion analysis with Pb exposure, age, and bio-
markers of kidney function. Men’s urinary
Pb excretion did not correlate with age or
with any of the three renal biomarkers tested.
Women’s urinary Pb excretion did not corre-
late with age, but it correlated with all three
kidney toxicity markers, with the greatest cor-
relation strength being between urinary Pb and
NAG excretion (r = 0.50, p < 0.001), followed
by urinary Pb and β2-MG excretion (r = 0.36,
p = 0.002) and urinary Pb and protein excre-
tion (r = 0.31, p = 0.01). We undertook partial
correlation with controlling for Cd excretion
because urinary excretion of the renal function
biomarkers protein and NAG showed also sig-
niﬁcant correlations with urinary Cd (Table 2).
The correlation between NAG and urinary Pb
excretion was maintained (partial r = 0.39,
p = 0.001) after controlling for Cd. The corre-
lations between Pb and urinary protein (partial
r = 0.09, p = 0.47) and between Pb and β2-MG
excretion rates (partial r = 0.16, p = 0.19) both
were lost after controlling for Cd.
Table 4 shows the dose–response relation-
ship between Cd body burden and nephro-
pathy as measured by increases in urinary
excretion of NAG. The prevalence of subjects
with abnormal urinary excretion of NAG
(NAG-nuria) in low, average, above average,
and high Cd body burden group was 3, 8,
and 23%, respectively. Prevalence of subjects
with NAG-nuria differed significantly across
the three Cd body burden groups (linear
trend chi-squared = 4.4, p = 0.04).
Table 5 shows the correlation matrix for
CYP2A6 activity, age, urinary Zn excretion
together with Cd, and Pb exposure in men and
women, separately. Two men and one woman
were not included in this correlation matrix
because they did not excrete 7-OHC. Urinary
Cd, Zn, and Pb correlated strongly with each
other, with r-values of 0.55 and 0.53 in men
and of 0.34 and 0.43 in women (p ≤ 0.001).
Thus, partial correlation analysis was under-
taken to control for Zn versus urinary 7-OHC
excretion. In men, urinary 7-OHC excretion
rates showed a positive correlation with urinary
Cd (r = 0.32, p = 0.01), whereas it did not
show any correlation with age or urinary Zn
excretion. In addition, there was a signiﬁcant
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Table 1. Age, blood, and urine chemistry proﬁles and assessment of Cd and Pb exposure and markers of
liver and kidney effects.
Descriptor Men Women
No. of subjects 53 65
Age (years) 36.7 ± 9.4 (21–57) 38.1 ± 8.3 (23–55)
Body mass index (kg/m2)a 23.1 ± 3.0 22.4 ± 4.5
Hematological proﬁles
Hemoglobin (g/dL) 14.5 ± 1.0 12.2 ± 1.1**
Hematocrit (%) 43.5 ± 2.7 37.1 ± 2.8**
Red blood cells (× 106/µL) 5.3 ± 0.5 4.4 ± 0.4**
White blood cells (× 103/µL) 7.4 ± 2.4 7.2 ± 1.9
Serum and urine chemistry proﬁles
Ferritin (µg/L) 202 ± 161 (14–978) 60 ± 48 (3–197)**
Total protein (g/dL) 7.7 ± 0.5 7.7 ± 0.4
Plasma creatinine (mg/dL) 0.94 ± 0.12 0.66 ± 0.10**
Blood urea nitrogen (mg/dL) 12.6 ± 3.4 11.0 ± 2.5*
Serum Zn (mg/L) 1.38 ± 0.30 1.19 ± 0.16**
Urinary creatinine (mg/mL) 0.75 ± 0.71 0.61 ± 0.47
Urinary Zn excretion (µg/g creatinine) 371 ± 224 272 ± 164*
Cd and Pb exposure indicators
Urinary Cd (µg/g creatinine) 0.48 ± 0.36 (0.05–1.6) 0.54 ± 0.39 (0.09–2.4)
Urinary Zn:Cd (mmol Zn/nmol Cd) 1.91 ± 1.82 (0.5 –13) 1.35 ± 1.14 (0.2–5)*
Urinary Pb (µg/g creatinine) 1.3 ± 1.8 (0.1–12) 2.4 ± 1.1 (0.6–6.8)**
Serum Cd (µg/L) 0.55 ± 0.48 (0.05 –2.5) 0.48 ± 0.44 (0.05–3.2)
Serum Pb (µg/L) 4.2 ± 5.4 (1–28) 3.0 ± 2.2 (1–12)
Kidney toxicity indicatorsb
Protein (mg/g creatinine) 49 ± 47 (0.4 –121) 74 ± 67 (0.4–317)**
β2-MG (µg/g creatinine) 51 ± 121 (0.03–762) 29 ± 38 (0.03–218)
NAG (U/g creatinine) 4.4 ± 2.6 (0.6–15) 4.6 ± 2.2 (0.7–12)
Liver effect indicator
Urinary 7-OHC (mg/3 hr)c 5.0 ± 2.6 (0–11) 5.1 ± 3.5 (0–15)
Values are mean ± SD; numbers in parentheses are ranges.
aBody mass index = body weight/square of height (kg/m2). bUrine samples were collected for 3 hr after administration of
15 mg of coumarin. cTwo men and one woman did not excrete 7-OHC in urine, most likely due to their lack of the CYP2A6
gene or having a defect in the CYP2A6 gene expression. *p = 0.001–0.005; **p < 0.001.inverse correlation between urinary 7-OHC
and Pb (r = –0.32, p = 0.001) in men after
adjusting for urinary Zn excretion. Multiple
regression controlling for age and urinary Zn
excretion confirmed a positive association
between urinary Cd and 7-OHC excretion
(adjusted β = 0.38, t = 2.9, p = 0.006) together
with a negative association between urinary Pb
and 7-OHC excretion (adjusted β = –0.29,
t = 2.2, p = 0.003). As in men, women’s urinary
7-OHC excretion rates showed a positive cor-
relation with urinary Cd (r = 0.21, p = 0.01),
whereas it did not show any correlation with
age or urinary Zn excretion. However, no
correlation between urinary 7-OHC and Pb
(r = 0.18, p > 0.05) was seen in women. Of
note, women’s urinary Zn excretion showed
an inverse correlation with age (r = –0.24,
p = 0.01–0.05), but no such correlation was
seen in men.
Figure 2 shows a correlation between rates
for hepatic CYP2A6-mediated coumarin
metabolism and urinary excretion of the
marker of renal tubular toxicity NAG in men
and women, separately. The Pearson’s r-value
for the correlation was 0.39 (p = 0.002) in
men and 0.37 (p = 0.001) in women.
Discussion
Age- and Zn-related increment in Cd burden
in men versus women. A lack of an active bio-
chemical process for Cd elimination coupled
with renal reabsorption of Cd from the ﬁltrate
predicts age-related increment of Cd accumu-
lation in various tissues and organs, notably
liver and kidney (IPCS 1992; Jarup et al. 1998,
Satarug et al. 2002). Thus, a positive correla-
tion between subjects’ Cd burden and age is
expected. Indeed, such expected correlation
was observed with greater correlative strength
and higher statistical significance in men
(r = 0.47, p < 0.001) than in women (r = 0.20,
p = 0.06). Body iron store status, however, did
not show any correlation with women’s or
men’s Cd burden, although a strong inﬂuence
of body iron store status on Cd burden was
shown previously in a group of women who
were almost 10 years younger than the women
in the present study (Satarug et al. 2004b).
Thus, such discrepancy was most likely due
to age-related differences in body iron status
in women because it is known that women’s
iron status is restored to normal at older ages
(Custer et al. 1995). As with iron status, Zn is
another important determinant of Cd burden
and toxicity (Goyer 1997; Madden and Fowler
2000; Satarug et al. 2000). Thus, the correla-
tion between age and Cd burden in women
may be insigniﬁcant because the women’s Cd
burden is more closely related to Zn status
than iron status at older ages when their iron
status becomes normal. Indeed, women’s uri-
nary Zn excretion showed an inverse cor-
relation with age (r = –0.24, p = 0.01–0.05;
Table 5), but no such correlation was seen in
men. We saw this as evidence for inﬂuence of
Zn status on Cd burden. In addition, it pro-
vides an explanation for greater strength of
the correlation between urinary Cd and Zn in
men (r = 0.55, p < 0.001) than in women
(r = 0.34, p = 0.001–0.005). A positive cor-
relation between urinary Cd and Zn was
expected in view of the fact that most of the
Cd excreted in urine is bound to the low-
molecular-weight metal-binding protein
metallothionein together with Zn (Goyer
1997; Madden and Fowler 2000). Further
research to show direct evidence for inﬂuence
of Zn status on Cd burden and toxicity in
women is required, and it should be focused
on menopausal women because increased sen-
sitivity to metal toxicity is noted in women
(Nishijo et al. 2004; Vahter et al. 2002).
Role of Zn in protection against Pb renal
toxicity. Women in the present study were
more exposed to Pb than were men, as reﬂected
by a 46% higher urinary Pb excretion rate
in women than in men (p < 0.001; Table 1).
Such Pb exposure levels experienced by these
women appeared to have produced mild
nephropathy, reﬂected by a signiﬁcant correla-
tion between urinary Pb and NAG, even after
controlling for urinary Cd excretion (partial
r = 0.39, p < 0.001). The Pb-linked renal
effect seen here is consistent with literature
reports (Madden and Fowler 2000) and a
recent study where urinary NAG excretion
was found to correlate positively with duration
of Pb exposure, blood Pb, and nail Pb in
policemen who were chronically exposed to
the metal in polluted air (Mortada et al.
2001). In animal studies, Zn has consistently
been shown to provide protection against Cd
and Pb accumulation and toxicity (Furst
2002; Goyer 1997), but there is little research
on such a role of Zn in humans. Our ﬁnding
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Figure 1. Frequency distribution of men and women across (A) Cd-burden groups, (B) Pb-burden groups, and (C) CYP2A6 phenotype groups, classed by percentile
ranking. (A) Frequency distribution of men and women across Cd-burden group did not show statistically signiﬁcant differences (likelihood ratio chi-squared =
2.6, p = 0.46). Cd-burden group was based on percentile ranking of rate of urinary Cd excretion: low, 5–30 ng/3 hr; average, 31–138 ng/3 hr; above average,
144–225 ng/3 hr; high, 235–360 ng/3 hr. (B) Difference in frequency distribution of men and women across Pb-burden group was statistically significant
(chi-squared = 18, p < 0.001). Pb-burden group was based on percentile ranking of urinary Pb excretion: low, 0.01–0.14 µg/3 hr; average, 0.15–0.42 µg/3 hr; above
average, 0.43–0.53 µg/3 hr; high, 0.54–1.01 µg/3 hr. (C) Null phenotype included three subjects (two men and one woman) who did not excrete any 7-OHC in the
urine collected for 3 hr after dosing with 15 mg of coumarin. Frequency distributions of men and women across CYP2A6 phenotype groups tended to be different
(likelihood ratio chi-squared = 7.3, p = 0.06). CYP2A6 phenotype group was based on percentile ranking of urinary excretion of 7-OHC in 3 hr after dosing with
15 mg of coumarin: null, 0 mg/3 hr; slow, 0.7–2.2 mg/3 hr; average, 2.5–6.8 mg/3 hr; rapid, 7.0–9.3 mg/3 hr; very rapid, 10.4–15.2 mg/3 hr.
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Table 2. Correlation between urinary Cd excretion rates, age, iron store status, and markers of glomerular
and tubular functions.
Men Women All subjects
Variables r-Value p-Value r-Value p-Value r-Value p-Value
Age 0.47a < 0.001 0.20a 0.06 0.25a 0.003
Iron store status –0.01a 0.46 0.17a 0.09 0.06a 0.26
Kidney function biomarkers
Urine protein 0.23 0.05 0.30 0.01 0.27 0.003
Urine β2-MG 0.20 0.07 0.09 0.23 0.14 0.06
Urine NAG 0.51a < 0.001 0.44a < 0.001 0.49a < 0.001
The r-values are the Spearman’s rank correlation coefﬁcients unless otherwise speciﬁed. Signiﬁcance of the correlation
between each pair of variables in row and column is identiﬁed by the p-values ≤0.05. 
aPearson’s r-correlation coefﬁcient value.on the absence of evidence for Pb-linked renal
toxicity in men was likely caused by lower Pb
exposure levels coupled with higher protective
factors in men than in women. Consistent
with the protective role of Zn, men in the pre-
sent study had 36% higher urinary Zn excre-
tion together with higher Zn:Cd and Zn:Pb
ratios than did women (p = 0.001–0.005).
Concurrent renal and liver effects of Cd
and Pb. Cd exposure levels experienced by
men and women in the present study were
sufficient to cause a mild (subclinical) renal
toxicity. This was suggested by a positive
correlation between urinary Cd and NAG
excretion rates in both men and women, after
controlling for age (r ~ 0.5, p < 0.001). Renal
tubular effects of exposure to low levels of
environmental Cd detected in the present
study conﬁrmed data from population studies
in Belgium (Buchet et al. 1990), China (Jin
et al. 2002), Japan (Ikeda et al. 2000; Oo
et al. 2000), the United States (Noonan et al.
2002), Sweden (Jarup 2002), and Thailand
(Satarug et al. 2004a, 2004b). Further, a
Cd-dose–dependent rise in the prevalence of
abnormal urinary NAG excretion (NAG-uria)
in subjects was shown (Table 4). The probabil-
ity of having NAG-uria was increased by 20%
as Cd burden increased from 0.05–0.26 µg/g
creatinine to 1–2.36 µg/g creatinine.
We used rate of coumarin 7-hydroxylation
as a marker of Cd and Pb liver effects because
the reaction is known to be catalyzed exclu-
sively by CYP2A6, which is expressed pre-
dominantly in the liver (Rautio et al. 1992;
Satarug et al. 1996, 2004a; Ujjin et al. 2002).
Evidence for liver Cd effect was suggested by
a positive correlation between CYP2A6 activity
and Cd burden seen in men and women,
which remained statistically significant after
controlling for age (Table 5). Such correlation
agreed with the data in a previous study
(Satarug et al. 2004a). However, despite over-
all similarity in Cd burden of subjects in the
two sample groups, the strength of correlation
between CYP2A6 activity and Cd burden was
weaker in the present sample group (r = 0.21
in women and r = 0.32 in men) than in the
previous group (r ~ 0.50 in men and women).
This result was probably due to the smaller
number of subjects combined with higher Pb
exposure in the subjects in the present sample
group than in the previous sample.
Evidence for Pb being a suppressor of
liver CYP2A6 comes from a multiple regres-
sion analysis, controlling for Zn excretion and
age, which revealed a negative association
between urinary Pb and CYP2A6 activity
(adjusted β = –0.29, p = 0.003) in men. The
Pb suppressive effect on liver CYP2A6 seen
here supports ﬁndings from previous reports
on diminished phenazone metabolism in
Pb-exposed workers (Fischbein et al. 1977;
Meredith et al. 1977). In contrast with results
in men, such inverse correlation between
CYP2A6 activity and Pb exposure was not
detected in women, although women showed
higher urinary Pb excretion than did men.
However, a weak correlation between CYP2A6
activity and Cd burden in women appeared
consistent with Pb being a suppressor of liver
CYP2A6 expression. The phenotype of hepatic
CYP2A6 has been shown to be under the
influence of liver pathophysiologic state,
smoking, and exposure to a number of drugs
and environmental factors (Kraul et al. 1991;
Pasanen et al. 1997; Satarug et al. 1996,
2004c; Sotaniemi et al. 1995). Further, a
recent study in 18 young male African green
monkeys showed that exposure to nicotine at
daily dose rates between 0.05 and 0.3 mg/kg
for 18 days depressed catalytic activity of
hepatic CYP2A6-like enzyme (Schoedel et al.
2003). It is therefore conceivable that a lack
of an inverse correlation between Pb burden
and CYP2A6 activity in women in the pre-
sent study was more likely due to differences
in dietary habits and exposure to the uniden-
tified substances that can increase CYP2A6
expression, thereby offsetting the Pb effect.
Finally, evidence for concurrent effects
of Cd in the liver and kidney comes from a
positive correlation observed between the
marker of kidney effect (urinary NAG
excretion) and rate of hepatic CYP2A6-
mediated metabolism (Figure 2). Highly
statistical significance was observed for both
men (p = 0.002) and women (p = 0.001),
although the strength of correlation was
modest in men (r = 0.39) and in women (r
= 0.37). We further note that similar
strength of correlation between urinary
NAG excretion and CYP2A6 activity in
men and women despite a weaker correla-
tion between urinary Cd excretion and
CYP2A6 activity in women than in men
(Table 5). This may be caused by a very
strong correlation between Cd concentra-
tions in liver and kidney and between uri-
nary NAG excretion and Cd concentration
in the kidney, consistent with autopsy data,
which showed that liver and urinary Cd
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Table 3. Correlation between urinary Pb excretion rate, age, and markers of glomerular and tubular functions.
Men Women All subjects
Variables r-Value p-Value r-Value p-Value r-Value p-Value
Age 0.13a 0.17 –0.14a 0.13 0.02a 0.43
Kidney function biomarkers
Urine protein 0.22 0.06 0.31 0.01 0.27 0.002
Urine β2-MG 0.12 0.19 0.36 0.002 0.21 0.01
Urine NAG 0.08a 0.27 0.50a < 0.001 0.22a 0.007
The r-values are the Spearman’s rank correlation coefﬁcients unless otherwise speciﬁed. Signiﬁcance of the correlation
between each pair of variables in row and column is identiﬁed by the p-values ≤ 0.05. The correlation between NAG and
urinary Pb excretion was maintained (partial r = 0.39, p = 0.001) after controlling for Cd. The correlations between Pb and
urinary protein (partial r = 0.09, p = 0.47) and between Pb and β2-MG excretion rates (partial r = 0.16, p = 0.19) were lost.
aPearson’s r-correlation coefﬁcient value.
Table 4. Dose–response relationship between Cd exposure and prevalence of NAG-nuria.
Urine NAG (units/g creatinine)
Percentile Urinary Cda < 2.5 3–5 6–7 ≥ 8 NAG-nuria (%)b
1st–25th 0.05–0.26 10 14 8 1 1/33 (3)
26th–90th 0.27–0.95 15 31 20 6 6/72 (8)
91st–100th 1.00–2.36 2 4 4 3 3/13 (23)
aµg/g creatinine. bUrinary excretion of NAG ≥ 8 U/g creatinine, which indicates statistically significant differences in
prevalence of subjects across urine–Cd and urine–NAG groups (linear trend chi-squared = 4.4, p = 0.04).
Table 5. Correlation matrix for rate of coumarin 7-hydroxylation, age, markers of renal tubular function,
and Cd and Pb exposure.
Variablesa Urinary 7-OHC Urinary Cd Age Urinary Pb Urinary Zn
Male nonsmokers (n = 51)
Urinary Cd 0.32* 1.00
Age 0.09 0.47# 1.00
Urinary Pb –0.32b 0.19 0.13 1.0
Urinary Zn 0.11 0.55# 0.21 0.53# 1.00
Female nonsmokers (n = 64)
Urinary Cd 0.21* 1.0
Age –0.07 0.20 1.0
Urinary Pb 0.18 0.39** –0.14 1.0
Urinary Zn 0.14c 0.34** –0.24* 0.43# 1.0
Numbers are Pearson correlation coefﬁcient (r) values unless otherwise speciﬁed.
aThe correlation analysis did not include two males and one female who did not excrete 7-OHC in urine, most likely due to
a lack of the CYP2A6 gene or having a defect in the CYP2A6 gene expression. bPartial correlation between urinary 7-OHC
and Pb after adjusting for urinary Zn. cPartial correlation between urinary 7-OHC and Zn, after adjusting for urinary Pb.
*p = 0.01–0.05; **p = 0.001–0.005; #p < 0.001.concentration are closely related (Satarug
et al. 2001).
Conclusions
Dietary Cd and Pb exposure at the levels
experienced by the subjects in the present
study is associated with variation in hepatic
CYP2A6 phenotypic expression and signs of
mild nephropathy, detectable at the renal
Cd concentrations of approximately 1–2
µg/g creatinine, corresponding to renal con-
centrations ≤ 50 µg/g kidney cortex. In
women, Zn status may be an important
determinant of Cd burden and Pb renal tox-
icity. In men, however, opposing effects of
Pb (a suppressor) and Cd (an inducer) on
phenotypic expression of hepatic CYP2A6 is
observed. Thus, exposure to environmental
Cd and possibly Pb may be implicated in
the rate of nicotine metabolism because
CYP2A6 is known to metabolize up to 90%
of nicotine (Oscarson 2001; Pelkonen et al.
2000; Raunio et al. 2001). In addition, Cd
and Pb exposure may explain differences
among individuals in their reaction to 
therapy with certain drugs and their ability
to handle a variety of environmental chemi-
cals that are metabolized by CYP2A6.
Associations between hepatic and renal
effects of exposure to environmental Cd and
possibly Pb observed in the present study
imply that elevated CYP2A6 activity occurs
in subjects who show signs of Cd-linked
renal toxicity.
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Figure 2. Pearson’s correlation analysis between rate of hepatic CYP2A6-mediated metabolism and the renal
tubular toxicity marker NAG. The lines represent a positive correlation between the renal tubular toxicity bio-
marker NAG excretion and hepatic CYP2A6 phenotype (urinary 7-OHC excretion after dosing with 15 mg of
the probe xenochemical coumarin) in men and women, separately. The Pearson’s correlation coefﬁcient
r-values (p-value) for men and for women were 0.39 (p = 0.002) and 0.37 (p = 0.001), respectively.
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